Public announcement of the company's current
R&D progress on anti-osteoporosis.
Date of events
2022/02/22
To which item it meets
paragraph 51
Statement
1.Date of occurrence of the event:2022/02/22
2.Company name:PhytoHealth Corporation
3.Relationship with the Company (please enter "the company itself" or
"subsidiaries"):the company itself
4.Reciprocal shareholding percentage:NA
5.Name of the reporting media:NA
6.Content of the report:NA
7.Cause of occurrence:
(1) In accordance with the provisions on financial statements disclosure,
the company makes a public announcement on the R&D progress of the
one new drugs currently in development.
(2) Concerning new drug R&D stages and workflow from bench to market,
please consult page 64 of the company's prospectus. As requested
by Taiwan Stock Exchange Corporation's letter No.1051801037 issued
on Mar.11,2016.
(3) New drug in development #1: Anti-osteoporosis
Clinical trial for preventing osteoporosis:
(a) Trial Title: PH3 for the Prevention of Osteoporosis in Post-
menopausal Women in Phase II, Double-Blind, Randomized, and
Placebo Controlled Study.
(b) Institution: TVGH, CGMH, NTUH and MMH.
(c) Trial Update: Phase II clinical study was completed. The company
continues to assess the compatibility of clinical trial
regulations between Taiwan and China and to explore clinical
trial cooperation possbility in accordance with clinical
trials harmonization.
(d) Filed IND annual report to US-FDA on 2021/05/03.
(e) Continuous monitoring of species identification and cultivation.
(f) The product development has achieved phased results, and will be
jointly developed at an appropriate time and after seeking
strategic partners.
8.Countermeasures:NA
9.Any other matters that need to be specified:NA
Attachments
Original Link
Original Document
Permalink
Disclaimer
PhytoHealth Corporation published this content on 22 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 February 2022 06:30:04 UTC.
PhytoHealth Corporation is a Taiwan company principally engaged in the research, development and manufacture of new botanical drugs. The Company's main products include western medicines, Chinese herbal medicines, cosmetics, Class B drugs and supplementary food. The Company also provides pharmaceutical consulting services. The Company distributes its products in domestic market and to overseas markets.